Hoosier Cancer Research Network investigators recently presented an abstract during the 2022 Gastrointestinal Cancers Symposium. The abstract included an online poster session featuring HCRN GI15-225, led by UNC Lineberger Comprehensive Cancer Center.

HCRN GI15-225, a pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma with preserved liver function, identified the concurrent administration of pembrolizumab with Y90 radioembolization demonstrated promising clinical activity with media time to progression and overall survival that exceeds historical data reported in similar patients treated with Y90 alone. With a 6-month progression free survival rate of 57.7% and a favorable toxicity profile, the combination of immune checkpoint blockade and Y90 deserves further evaluation in larger clinical trials. 

This multi-institution study enrolled subjects at three institutions including Fred Hutchinson Cancer Research Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the University of North Caroline at Chapel Hill. 

Authors include Autumn Jackson McRee, Paul R. Helft, William Proctor Harris, Hanna Kelly Sanoff, Matthew Johnson, Menggang Yu, Bert O’Neil

See abstract

About Hoosier Cancer Research Network

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.